JP2015514093A - 敗血症の処置のためのチモシンαの使用 - Google Patents

敗血症の処置のためのチモシンαの使用 Download PDF

Info

Publication number
JP2015514093A
JP2015514093A JP2015503582A JP2015503582A JP2015514093A JP 2015514093 A JP2015514093 A JP 2015514093A JP 2015503582 A JP2015503582 A JP 2015503582A JP 2015503582 A JP2015503582 A JP 2015503582A JP 2015514093 A JP2015514093 A JP 2015514093A
Authority
JP
Japan
Prior art keywords
sepsis
thymosin alpha
days
administered
alpha peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015503582A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015514093A5 (cg-RX-API-DMAC7.html
Inventor
シンシア タシル
シンシア タシル
シャンドン クワン
シャンドン クワン
チャンフェン ウー
チャンフェン ウー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sciclone Pharmaceuticals LLC
Original Assignee
Sciclone Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sciclone Pharmaceuticals LLC filed Critical Sciclone Pharmaceuticals LLC
Publication of JP2015514093A publication Critical patent/JP2015514093A/ja
Publication of JP2015514093A5 publication Critical patent/JP2015514093A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2015503582A 2012-03-30 2013-03-28 敗血症の処置のためのチモシンαの使用 Pending JP2015514093A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261618563P 2012-03-30 2012-03-30
US61/618,563 2012-03-30
US201261643824P 2012-05-07 2012-05-07
US61/643,824 2012-05-07
US13/835,107 US20130296223A1 (en) 2012-03-30 2013-03-15 Use of thymosin alpha for the treatment of sepsis
US13/835,107 2013-03-15
PCT/US2013/034394 WO2013149030A2 (en) 2012-03-30 2013-03-28 Use of thymosin alpha for the treatment of sepsis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017108931A Division JP2017214377A (ja) 2012-03-30 2017-06-01 敗血症の処置のためのチモシンαの使用

Publications (2)

Publication Number Publication Date
JP2015514093A true JP2015514093A (ja) 2015-05-18
JP2015514093A5 JP2015514093A5 (cg-RX-API-DMAC7.html) 2015-12-17

Family

ID=49261395

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2015503582A Pending JP2015514093A (ja) 2012-03-30 2013-03-28 敗血症の処置のためのチモシンαの使用
JP2017108931A Pending JP2017214377A (ja) 2012-03-30 2017-06-01 敗血症の処置のためのチモシンαの使用
JP2019120721A Pending JP2019156854A (ja) 2012-03-30 2019-06-28 敗血症の処置のためのチモシンαの使用
JP2021065044A Pending JP2021100983A (ja) 2012-03-30 2021-04-07 敗血症の処置のためのチモシンαの使用
JP2022161403A Pending JP2022176345A (ja) 2012-03-30 2022-10-06 敗血症の処置のためのチモシンαの使用
JP2025076491A Pending JP2025107346A (ja) 2012-03-30 2025-05-02 敗血症の処置のためのチモシンαの使用

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2017108931A Pending JP2017214377A (ja) 2012-03-30 2017-06-01 敗血症の処置のためのチモシンαの使用
JP2019120721A Pending JP2019156854A (ja) 2012-03-30 2019-06-28 敗血症の処置のためのチモシンαの使用
JP2021065044A Pending JP2021100983A (ja) 2012-03-30 2021-04-07 敗血症の処置のためのチモシンαの使用
JP2022161403A Pending JP2022176345A (ja) 2012-03-30 2022-10-06 敗血症の処置のためのチモシンαの使用
JP2025076491A Pending JP2025107346A (ja) 2012-03-30 2025-05-02 敗血症の処置のためのチモシンαの使用

Country Status (8)

Country Link
US (5) US20130296223A1 (cg-RX-API-DMAC7.html)
EP (2) EP3741386A1 (cg-RX-API-DMAC7.html)
JP (6) JP2015514093A (cg-RX-API-DMAC7.html)
KR (1) KR20150048663A (cg-RX-API-DMAC7.html)
CN (2) CN107519483A (cg-RX-API-DMAC7.html)
CA (1) CA2866435A1 (cg-RX-API-DMAC7.html)
HK (1) HK1246694A1 (cg-RX-API-DMAC7.html)
WO (1) WO2013149030A2 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019207684A (ja) * 2018-04-10 2019-12-05 ヒル−ロム サービシズ，インコーポレイテッド 医療施設の複数のソースからのデータに基づく患者リスク評価

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2956429A1 (en) * 2014-08-12 2016-02-18 Arsanis Biosciences Gmbh Predicting s. aureus disease
WO2019028448A1 (en) * 2017-08-04 2019-02-07 The Johns Hopkins University APPLICATION FOR EARLY PREDICTION OF SEPTIC SHOCK WAITING
LT3781210T (lt) * 2018-04-20 2024-09-10 Combioxin Sa Gydymas hipotenzijos su sepsiu arba septiniu šoku
EP4370129A1 (en) 2021-07-12 2024-05-22 2N Pharma ApS Carnitine-palmitoyl-transferase-1 (cpt-1) inhibitors for use in a method of preventing or treating sepsis in a mammalian subject

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995009647A1 (en) * 1993-10-07 1995-04-13 The George Washington University Medical Center METHOD OF TREATING SEPTIC SHOCK USING THYMOSIN-α¿1?
JP2002500189A (ja) * 1998-01-08 2002-01-08 エド・ガイストリヒ・ゼーネ・アクチエンゲゼルシャフト・フューア・ヒェーミシェ・インドゥストリー 微生物の院内感染症の治療用医薬の製造におけるタウロリジンまたはタウラルタムのような抗微生物薬剤の使用
CN101020048A (zh) * 2007-02-12 2007-08-22 广东天普生化医药股份有限公司 一种用于治疗脓毒症的药物组合物
JP2010522192A (ja) * 2007-03-21 2010-07-01 ボーシュ アンド ローム インコーポレイティド 抗菌薬耐性のバクテリアによって引き起こされる感染症を治療、軽減、寛解、又は予防するための組成物及び方法
WO2011104352A1 (en) * 2010-02-25 2011-09-01 Agennix Ag Oral lactoferrin in the treatment of severe sepsis

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4079127A (en) 1976-10-28 1978-03-14 Board Of Regents Of The University Of Texas Thymosin alpha 1
TW252045B (cg-RX-API-DMAC7.html) * 1993-10-07 1995-07-21 Allan L Goldstein
UA80957C2 (en) 2001-11-01 2007-11-26 Sciclone Pharmaceuticals Inc Method of administering a thymosin alpha 1 peptide
KR20050086819A (ko) * 2002-11-25 2005-08-30 시클론 파마수티컬 인코포레이티드 알파 티모신을 사용한 방사능 손상에 대한 보호방법
CA2622193A1 (en) * 2005-09-29 2007-04-12 Nektar Therapeutics Antibiotic formulations, unit doses, kits, and methods
JP2011506436A (ja) * 2007-12-12 2011-03-03 サイクローン・ファーマシューティカルズ・インコーポレイテッド 細胞傷害性ｔリンパ球抗原４（ｃｔｌａ４）に対する抗体と組み合わせられたアルファチモシンペプチドによる黒色腫の処置の方法
CN101514228A (zh) * 2008-02-21 2009-08-26 张卓兵 N-端修饰的人胸腺肽α1复合物及其制备方法
JP2012526149A (ja) * 2009-05-08 2012-10-25 サイクローン・ファーマシューティカルズ・インコーポレイテッド ワクチン増強剤としてのαチモシンペプチド
CA2826875A1 (en) * 2011-02-09 2012-08-16 Sciclone Pharmaceuticals, Inc. Thymosin alpha peptide for preventing, reducing the severity of, and treating infection

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995009647A1 (en) * 1993-10-07 1995-04-13 The George Washington University Medical Center METHOD OF TREATING SEPTIC SHOCK USING THYMOSIN-α¿1?
JP2002500189A (ja) * 1998-01-08 2002-01-08 エド・ガイストリヒ・ゼーネ・アクチエンゲゼルシャフト・フューア・ヒェーミシェ・インドゥストリー 微生物の院内感染症の治療用医薬の製造におけるタウロリジンまたはタウラルタムのような抗微生物薬剤の使用
CN101020048A (zh) * 2007-02-12 2007-08-22 广东天普生化医药股份有限公司 一种用于治疗脓毒症的药物组合物
JP2010522192A (ja) * 2007-03-21 2010-07-01 ボーシュ アンド ローム インコーポレイティド 抗菌薬耐性のバクテリアによって引き起こされる感染症を治療、軽減、寛解、又は予防するための組成物及び方法
WO2011104352A1 (en) * 2010-02-25 2011-09-01 Agennix Ag Oral lactoferrin in the treatment of severe sepsis

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHIN. CRIT. CARE MED. 2009, VOL.21, NO.1, P.21-24, JPN6016027709, ISSN: 0003362425 *
CHIN. CRIT. CARE MED., 2007, VOL.19, NO.3, P.153-155, JPN6016027716, ISSN: 0003362426 *
CHIN. CRIT. CARE MED., 2009, VOL.21, NO.3, P.147-150, JPN6016027712, ISSN: 0003362427 *
THE JOURNAL OF INFECTIOUS DISEASES, 2008, VOL.198, P.723-730, JPN6016027714, ISSN: 0003362428 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019207684A (ja) * 2018-04-10 2019-12-05 ヒル−ロム サービシズ，インコーポレイテッド 医療施設の複数のソースからのデータに基づく患者リスク評価
JP2020129396A (ja) * 2018-04-10 2020-08-27 ヒル−ロム サービシズ，インコーポレイテッド 医療施設の複数のソースからのデータに基づく患者リスク評価

Also Published As

Publication number Publication date
US20210106656A1 (en) 2021-04-15
JP2021100983A (ja) 2021-07-08
WO2013149030A2 (en) 2013-10-03
HK1207314A1 (en) 2016-01-29
CA2866435A1 (en) 2013-10-03
US20130296223A1 (en) 2013-11-07
EP3741386A1 (en) 2020-11-25
JP2017214377A (ja) 2017-12-07
CN107519483A (zh) 2017-12-29
EP2841088B1 (en) 2020-06-17
KR20150048663A (ko) 2015-05-07
EP2841088A2 (en) 2015-03-04
US20150024994A1 (en) 2015-01-22
JP2025107346A (ja) 2025-07-17
JP2019156854A (ja) 2019-09-19
CN105338996A (zh) 2016-02-17
US20240091314A1 (en) 2024-03-21
US20180236036A1 (en) 2018-08-23
JP2022176345A (ja) 2022-11-25
HK1246694A1 (zh) 2018-09-14
EP2841088A4 (en) 2015-10-14

Similar Documents

Publication Publication Date Title
JP2025107346A (ja) 敗血症の処置のためのチモシンαの使用
US11752190B2 (en) Modulators of complement activity
US11123399B2 (en) Modulators of complement activity
US20220257697A1 (en) Inflammatory disease treatment with complement inhibitors
ES2881201T3 (es) Tratamiento de la neumonía grave adquirida en la comunidad
US20200121773A1 (en) Compositions and methods for manufacturing bacteriophage cancer vaccines and uses thereof
CN103648515B (zh) 作为辐射缓和剂和辐射防护剂的bpi和其同源物
HK40035899A (en) Use of thymosin alpha for the treatment of sepsis
US20140213506A1 (en) Thymosin alpha peptide for preventing, reducing the severity of, and treating infection
HK1207314B (en) Use of thymosin alpha for the treatment of sepsis
TW202423978A (zh) 急性呼吸衰竭之治療
WO2023064373A1 (en) Targeting slc46a2-mediated muropeptide transport to treat psoriasis
WO2023022616A1 (ru) Способ профилактики или лечения коронавирусной инфекции
US20150031617A1 (en) Use of thymosin alpha for treatment of purulent rhinosinusitis
McNew et al. Fatal cryptococcosis presenting as hepatobiliary dysfunction in an ALL patient
HK1254810B (zh) 作为辐射缓和剂和辐射防护剂的bpi和其同源物的用途
HK1190875A (en) Thymosin alpha peptide for preventing, reducing the severity of, and treating infection

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150526

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151028

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151028

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160720

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161020

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161219

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170201